Related Experiment Video
Updated: Jan 23, 2026

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration
N Espinoza1, J Galdames1, D Navea1
1Laboratorio Clínico, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile.
Abstract:
Invasive fungal infections (IFIs) are the most frequent cause of morbidity and mortality in immunocompromised children. Voriconazole is the first-line antifungal choice in the treatment of IFIs like aspergillosis. Voriconazole pharmacokinetics vary widely among patients and voriconazole is metabolized mainly in the liver by the CYP2C19 enzyme, which is highly polymorphic. The CYP2C19*17 allele is characterized by the presence of four single nucleotide polymorphisms expressing an ultra-rapid enzyme phenotype with an accelerated voriconazole metabolism, is associated with low (sub-therapeutic) plasma levels in patients treated with the standard dose. Considering that in our center a high percentage of children have sub-therapeutic levels of voriconazole when treated with standard doses, we sought to determine the frequency of the CYP2C19*17 polymorphism (rs12248560) in a Chilean population and determine the association between voriconazole concentrations and the rs12248560 variant in immunocompromised children. First, we evaluated the frequency of the rs12248560 variant in a group of 232 healthy Chilean children, and we found that 180 children (77.6%) were non-carriers of the rs12248560 variant, 49 children (21.1%) were heterozygous carriers for rs12248560 variant and only 3 children (1.3%) were homozygous carriers for rs12248560 variant, obtaining an allelic frequency of 12% for variant in a Chilean population. To determine the association between voriconazole concentrations and the rs12248560 variant, we analyzed voriconazole plasma concentrations in a second group of 33 children treated with voriconazole. In these patients, carriers of the rs12248560 variant presented significantly lower voriconazole plasma concentrations than non-carriers (p = 0,011). In this study, we show the presence of the rs12248560 variant in a Chilean population and its accelerating effect on the pharmacokinetics of voriconazole in pediatric patients. From these data, it would be advisable to consider the variant of the patient prior to calculating the dosage of voriconazole.
Insights
The CYP2C19*17 genetic variant accelerates voriconazole metabolism in Chilean children, leading to sub-therapeutic drug levels. This finding suggests personalized dosing based on genetic profiles for better invasive fungal infection treatment.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Pediatric Infectious Diseases
Background:
- Invasive fungal infections (IFIs) pose significant risks for immunocompromised children.
- Voriconazole is a critical first-line treatment for IFIs, but its efficacy is hampered by variable pharmacokinetics.
- The CYP2C19 enzyme, responsible for voriconazole metabolism, exhibits significant genetic polymorphism.
Purpose of the Study:
- To determine the frequency of the CYP2C19*17 polymorphism (rs12248560) in a Chilean pediatric population.
- To investigate the association between the rs12248560 variant and voriconazole plasma concentrations in immunocompromised children.
- To inform personalized voriconazole dosing strategies in pediatric patients.
Main Methods:
- Genotyping for the rs12248560 variant in 232 healthy Chilean children.
- Analysis of voriconazole plasma concentrations in 33 immunocompromised children treated with the drug.
- Statistical analysis to compare voriconazole levels between carriers and non-carriers of the rs12248560 variant.
Main Results:
- The allelic frequency of the rs12248560 variant in the Chilean population was 12%.
- Children carrying the rs12248560 variant exhibited significantly lower voriconazole plasma concentrations compared to non-carriers (p=0.011).
- The CYP2C19*17 variant was associated with accelerated voriconazole metabolism.
Conclusions:
- The rs12248560 variant is present in the Chilean population and impacts voriconazole pharmacokinetics.
- Genetic screening for CYP2C19*17 may be beneficial for optimizing voriconazole dosage in immunocompromised children.
- Personalized dosing approaches considering genetic variations can improve treatment outcomes for IFIs.
Related Concept Videos
What is Population Genetics?
Frequency-dependent Selection
Conservation of Small Populations
Population Growth
Single Nucleotide Polymorphisms-SNPs
Concentration Cells
Consider the following voltaic cell:

